* Investment Date & Round, Invested in Seed round in 2017
* Initial Premoney Valuation $6M (most recently post money >$75M)
* Acquisition: TBD
* Exit Valuation: Next valuation should be >$120M
* Return Multiple: TBD

Mission Bio’s instrument and consumables prepares 1,000 to 10,000 individual cells in parallel, enabling single-cell sensitivity within customers’ existing DNA sequencing workflows.  

The South San Francisco-based company’s machine and software, called the “Tapestri” platform, launched commercially in 2017 and has been put to use studying cellular mutations inside tumors of diseases like acute myeloid leukemia (AML) at cancer research centers such as MD Anderson and Stanford University, as well as pharmaceutical companies. While traditional sequencing methods show the average molecular profile of all the cells in a patient’s sample, Tapestri’s single-cell capability allows researchers to scrutinize the DNA in any individual cell, thereby uncovering cancer-causing variation earlier than otherwise possible. Similarly, Tapestri is being used to monitor and troubleshoot gene modifications (CRISPR edits) that drug developers are seeking to use to treat genetic diseases.  
​
Gary Zweiger met the founding team while they were still supported by grants at the University of California’s QB3 incubator. Dr. Zweiger continues to support the company as an Advisor. ​